Trial Profile
A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Vx 001 (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Dec 2015 New trial record